Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioma 11Glioblastoma 6Brain Neoplasms 4Neuroendocrine Tumors 3Hypoglycemia 3Congenital Hyperinsulinism 3Recurrence 2Parkinson Disease 2Oligodendroglioma 2Neuroblastoma 2Insulinoma 2Hyperinsulinism 2Gliosarcoma 2Ependymoma 2Astrocytoma 2Pheochromocytoma 1Parkinsonian Disorders 1Parathyroid Neoplasms 1Optic Nerve Glioma 1Neoplasms, Neuroepithelial 1Neoplasms 1Multiple Endocrine Neoplasia 1Lewy Body Disease 1Infant, Newborn, Diseases 1Hyperparathyroidism 1Hypercalcemia 1Glucose Metabolism Disorders 1Glioma, Subependymal 1Endocrine System Diseases 1Carcinoma, Medullary 1

Interventions

fluorodopa F 18 1Magnetic Resonance Spectroscopy 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Parkinsonian Disorders × fluorodopa F 18 × Clear all
NCT07542158 2026-04-21

Ultralow Dose PET Imaging of 18F-FDOPA

Nuclear Imaging Institute

Phase 2 Enrolling by invitation
200 enrolled
CNS

Glioma, Neoplasms, Parkinsonian Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡